Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-519 in Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Jan 2029
- Countries
- 2
01
Overview
Phase 1, open-label trial of ABBV-519 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Change from Baseline in B Cells in Blood at 365 days, Maximum Plasma Concentration of ABBV-519 at 85 days and 5 more. Started May 2026; status: recruiting.
02
Drugs
ABBV-519
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07607964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607964.